About Us: Relburn is a team of smart, dedicated and high-energy individuals who appreciate a challenging entrepreneurial environment and who contribute daily to our company objectives. We are committed to aggressively leveraging our expertise in inflammation and drug discovery, development, and commercialization.
Our Mission: Relburn is a biopharmaceutical company focused on the identification, development and commercialization of drugs that alter the inflammatory process. Our strategy is to maximize value through excellence in performance and innovation, while maintaining the highest standards of integrity and leadership. Relburn is committed to developing innovative products to better the lives of people with chronic inflammatory disorders. The Company’s lead programs are in NASH and chronic gout.
About Metabolomics: “Chronic human illness commonly results from dysfunction in multiple physiologic pathways, and discovery strategies based on concepts of “one-target, one-disease” are proving increasingly unsuccessful. Metabolomics has driven an interest in agents that modulate multiple targets simultaneously. Targeting cellular function as a system, rather than at a single-target, may lead to novel classes of effective multi-targeted drugs with fewer side-effects.”*
Following this principle, Relburn uses a single small molecule to inhibit multiple targets in a well-known inflammatory pathway that initiates both NASH and gout. These targets affect a chemical equilibrium that simultaneously reduces production as well as enhances excretion of a toxic substance, uric acid, which is believed to be a proximal cause of multiple inflammatory diseases.
*Paragraph adapted from Schrattenholz A, et al: Methods Mol Biol. 662:29-58, 2010.